# Open Orphan appoints Liberum Capital Limited as its Nominated Adviser and Joint Broker

- Link: https://www.directorstalkinterviews.com/open-orphan-appoints-liberum-capital-limited-as-its-nominated-adviser-and-joint-broker/4121062585
- Published: 2022-04-28T07:04:37+01:00
- Author: Giles

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
a rapidly growing specialist contract research organisation (CRO) and world leader
in testing infectious and respiratory disease products using human challenge clinical
trials, has announced that further to the announcements by Arden Partners Plc on
11 and 14 April 2022 regarding the loss of its Nominated Adviser status upon the
completion of its recommended takeover, the Company has appointed Liberum Capital
Limited as its Nominated Adviser and Joint Broker. Given the timing of the completion
of the recommended takeover of Arden Partners Plc, the Exchange has agreed that 
subject to initial due diligence being undertaken, Liberum has until 5pm on 27 July
2022 to complete its full due diligence.

There can be no guarantee on the outcome of the full due diligence and its impact
on Liberum’s decision to continue to act as Nominated Adviser. Accordingly, in such
circumstances there is a risk that if the Liberum does not continue to act as Nominated
Adviser following completion of its full due diligence and the Company has not found
an alternative Nominated Adviser, the Company’s AIM securities may be suspended 
pursuant to AIM Rule 1. If within one month of that suspension, the Company has 
failed to appoint a replacement Nominated Adviser, the admission of its AIM securities
will be cancelled.

Notwithstanding the extension of time provided in respect of completing full due
diligence obligations at engagement, Liberum will continue to be subject to all 
the ongoing Nominated Adviser responsibilities under the AIM Rules for Nominated
Advisers.

finnCap plc and Davy will continue to act as the Company’s Joint Brokers.

> **Yamin ‘Mo’ Khan, Chief Executive Officer at Open Orphan, said: **_“As the market
> is aware, Arden Partners can no longer act as Nomad for listed companies from 
> 29 April 2022 and as such, we thank them for their support over the past number
> of years. We are delighted to now be working with such a prestigious investment
> bank as Liberum.”_

Open Orphan plc is a rapidly growing contract research company that is a world leader
in testing infectious and respiratory disease products using human challenge clinical
trials. The Company provides services to Big Pharma, biotech, and government/public
health organisations.

The Company has a leading portfolio of human challenge study models for infectious
and respiratory diseases, including the recently established COVID-19 model, and
is developing a number of new models, such as Malaria, to address the dramatic growth
of the global infectious disease market. The Paris and Breda offices have over 25
years of experience providing drug development services such as biometry, data management,
statistics CMC, PK and medical writing to third party clients as well as supporting
the London-based challenge studies.

Share on:
